Wells Fargo’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
VCM
MCM
TSC
PCM
SS
Wells Fargo's LUCD Position: Q1 2026 in Review
Wells Fargo increased its Lucid Diagnostics (LUCD) stake by 39% in Q1 2026, buying an estimated $452K and bringing the position to 1,274,390 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3505.
Wells Fargo first reported a position in LUCD in Q4 2021 and has held it in 18 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.
- Wells Fargo held 1,274,390 shares of Lucid Diagnostics worth $1.47M as of Q1 2026.
- Wells Fargo bought 354,911 Lucid Diagnostics shares in Q1 2026, an estimated $452K.
- Lucid Diagnostics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3505 holding.
- Wells Fargo first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 18 quarters since.
- 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.